LRCX vs SLRX · P/E 71, rev $23.23B vs $4.9M cap
Lam Research Corp (LRCX) versus Salarius Pharmaceuticals Inc (SLRX) — a side-by-side from cached financials, not a winner call.
Lam Research Corp (LRCX) is a semiconductor equipment & materials company listed on NASDAQ. It is led by Timothy M. Archer.
Salarius Pharmaceuticals Inc (SLRX) is a biotechnology company listed on NASDAQ.
Latest reported LRCX revenue for 2026-06-28 was $23.23B. Net income was $7.27B. Revenue was up 26.0% from 2025-06-29 to 2026-06-28. LRCX currently screens at market cap $467.94B and trailing P/E 70.9.
Latest reported SLRX revenue for 2023-03-31 was $0. Net income was -$5.3M. SLRX currently screens at market cap $4.9M.
LRCX currently screens at market cap $467.94B and trailing P/E 70.9. SLRX currently screens at market cap $4.9M.
Not investment advice. Open the LRCX and SLRX stock pages for the full models.
Not investment advice.